STRO (Sutro Biopharma) Additional Paid-In Capital: $951.70 Mil(As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STRO Sutro Biopharma Inc STRO
47 GF Score
Price $18.36
GF Value $5.30
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Sutro Biopharma Additional Paid-In Capital?

Sutro Biopharma STRO -4.00% 47 Additional Paid-In Capital is $951.70 Mil as of Jun. 2026. GuruFocus rates STRO with a GF Score™ of 47/100 and a GF Value™ of $5.30 (Significantly Overvalued). The stock has 4 warning signs investors should review.


Sutro Biopharma's quarterly additional paid-in capital increased from Dec. 2025 ($845.48 Mil) to Mar. 2026 ($949.64 Mil) and increased from Mar. 2026 ($949.64 Mil) to Jun. 2026 ($951.70 Mil).

Sutro Biopharma's annual additional paid-in capital increased from Dec. 2023 ($708.98 Mil) to Dec. 2024 ($831.42 Mil) and increased from Dec. 2024 ($831.42 Mil) to Dec. 2025 ($845.48 Mil).

Sutro Biopharma Additional Paid-In Capital Related Terms

Sutro Biopharma Additional Paid-In Capital Historical Data

* Premium members only.

The historical data trend for Sutro Biopharma's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sutro Biopharma Additional Paid-In Capital Chart

Sutro Biopharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Additional Paid-In Capital
Get a 7-Day Free Trial Premium Member Only Premium Member Only 586.24 670.22 708.98 831.42 845.48

Sutro Biopharma Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Additional Paid-In Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 842.15 843.81 845.48 949.64 951.70
STRO
47GF Score
Sutro Biopharma Inc STRO
Additional Paid-In Capital is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sutro Biopharma Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital=(Issue Price-Par Value)* Shares Outstanding (Diluted Average)
What does a Additional Paid-In Capital of $951.70 Mil mean?
Sutro Biopharma (STRO) has a Additional Paid-In Capital of $951.70 Mil as of Jun. 2026. Additional paid-in capital is the capital a company raises in excess of par value. View historical data on Sutro Biopharma and its competitors.
Is Sutro Biopharma's Additional Paid-In Capital too high?
Sutro Biopharma's current Additional Paid-In Capital is $951.70 Mil. Overall, Sutro Biopharma has a GF Score™ of 47/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Sutro Biopharma's Additional Paid-In Capital compare to ABEO and IKT?
Sutro Biopharma's Additional Paid-In Capital of $951.70 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Additional Paid-In Capital for a Biotechnology company?
A good Additional Paid-In Capital depends on the Biotechnology industry context. However, Additional Paid-In Capital should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Additional Paid-In Capital mean?
A high Additional Paid-In Capital can signal that a stock is expensive relative to its fundamentals. Additional paid-in capital is the capital a company raises in excess of par value. View historical data on Sutro Biopharma and its competitors. Sutro Biopharma's current Additional Paid-In Capital is $951.70 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sutro Biopharma stock overvalued right now?
Based on GuruFocus' analysis, Sutro Biopharma (STRO) is currently considered Significantly Overvalued. The stock's GF Value™ is $5.30, compared to a current price of $18.36 — trading 246.3% above its estimated fair value. The current Additional Paid-In Capital is $951.70 Mil. Sutro Biopharma's overall GF Score™ is 47/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Additional Paid-In Capital calculated?
Additional Paid-In Capital is calculated from a company's financial statements. For Sutro Biopharma (STRO), the current Additional Paid-In Capital is $951.70 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sutro Biopharma (STRO) Overvalued in 2026?

Based on GuruFocus' analysis, Sutro Biopharma stock appears to be overvalued. The current stock price of $18.36 is trading 246.3% above its estimated GF Value™ of $5.30. GuruFocus considers Sutro Biopharma to be Significantly Overvalued.

Key valuation signals for STRO:

  • Additional Paid-In Capital: $951.70 Mil
  • GF Value™: $5.30 vs. price of $18.36 (246.3% above fair value)
  • GF Score™: 47/100 with 4 warning signs

No single metric tells the full story. See the STRO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sutro Biopharma Business Description

Other Exchanges S090:Germany
Address 111 Oyster Point Boulevard, South San Francisco, CA, USA, 94080
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. Company's wholly-owned product candidate is STRO-004, a single homogeneous ADC directed against tissue factor which are developing for the treatment of solid tumors. The company also pipeline contains STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.
47GF Score

Get the complete analysis for STRO

Additional Paid-In Capital is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$18.36
Price
$5.30
GF Value